This study investigates the use of digital and standardized documentation by patients of frequently occurring adverse events in oncological therapies.

This research study is structured as a Phase I and II clinical trial. In phase I, the feasibility of using a smartphone application to document adverse events that have occurred during oncological therapies by the patient will be investigated. In phase II we will investigate whether the use of the smartphone app allows an improvement of patient care by reducing occurred adverse events.

Inclusion Criteria:

• infusional combination therapy with at least two chemotherapy substances with or without further targeted therapies
• combination of at least two immune-checkpoint inhibitors
• able to read and understand German

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded:

• severe neurological disorders
• severe psychiatric disorders

Phase I:

- 30 participants in total non-randomly divided into three age groups (< 55 years, 55-75 years, > 75 years) of 10 people each.

Phase II:

- 36 participants randomly assigned a group of 18 persons (smartphone users, non-smartphone users)